Business

Manhattan Scientifics Recruits Robert R. Proulx as Its New President and Chief Operating Officer for Its Senior Scientific Subsidiary

Manhattan Scientifics Recruits Robert R. Proulx as Its New President and Chief Operating Officer for Its Senior Scientific Subsidiary.

articleManhattan Scientifics, Inc.January 14, 20153/company/manhattan-scients/news/manhattan-scientifics-recruits-robert-r-proulx-as-its-new-president-and-chief-operating-officer-for-its-senior-scientific-subsidiary
Manhattan Scientifics Recruits Robert R. Proulx as Its New President and Chief Operating Officer for Its Senior Scientific Subsidiary

About this update from Manhattan Scientifics, Inc.

[{"type":"text","content":"\n \n Manhattan Scientifics, Inc. (OTCQB:MHTX) has recruited Robert R. Proulx \n (pronounced “Pru”) to the position of President and Chief Operating \n Officer of its Senior Scientific LLC subsidiary, effective January 12. \n As previously announced, Gerald Grafe, former president of Senior \n Scientific, is remaining with Senior Scientific to focus on strategic \n relationships and intellectual property issues. Edward R. Flynn, PhD, \n founder of Senior Scientific, is remaining as Chief Scientist.\n \n \n Mr. Proulx’s responsibilities will include building Senior Scientific’s \n core capabilities in nano-particle technology and expanding on the \n collaborations in place with the MD Anderson Cancer Center in Houston \n and The University of New Mexico Health Sciences Center, Albuquerque, to \n help further develop and strategically position Senior Scientific’s MRX \n diagnostic technology for the non-invasive early detection of cancer.\n \n \n Mr. Proulx, age 57, is a veteran business executive with more than 25 \n years of leadership experience for both private and public companies in \n the life science and diagnostic device markets. Most recently, he served \n as Chief Commercial Officer and General Manager of U.S. Operations for \n Silicon Biosystems, Inc., whose image-based cell sorting technology is \n advancing personalized medicine initiatives in cancer through the \n molecular characterization of tumor heterogeneity. Earlier, he served as \n Vice President, Marketing & Sales at Nanogen, Inc., where he was \n responsible for worldwide corporate branding, product marketing and \n North American sales operations for the company’s in vitro diagnostic \n products. Prior to this, he held senior-level positions at Gene Logic \n Inc.; IGEN International, Inc.; Packard Instrument Company, Inc. and \n Bio-Tek Instruments, Inc. He has served on the board of directors of \n Semrock and PGXL Diagnostic Laboratories and has been a volunteer in the \n CONNECT Springboard Entrepreneurs in Residence program, helping nurture \n startups through early-stage business planning. His bachelor’s and \n master’s degrees are from The State University of New York at Albany and \n he is a graduate of the Executive Management Program at The Pennsylvania \n State University Smeal College of Busine...

More updates from Manhattan Scientifics, Inc.